Poster
Quizartinib
ACoP16 | October 18-21, 2025
Hematology
Exposure-overall survival analysis for quizartinib in newly diagnosed patients with FMS-like tyrosine kinase 3-internal-tandem-duplication-positive acute myeloid leukemia
Giovanni Smania
Poster
Dato-DXd
ACoP16 | October 18-21, 2025
Breast Cancer
Exposure-response analyses of datopotamab deruxtecan (Dato-DXd) in patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer
Zoey Tang
Poster
Dato-DXd
ACoP16 | October 18-21, 2025
Lung Cancer
Exposure-response analysis of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in patients with advanced or metastatic non-small cell lung cancer
Jaydeep Sinha
Poster
Quizartinib
ACoP16 | October 18-21, 2025
Hematology
Physiologically based pharmacokinetic modeling of quizartinib to assess drug-drug interaction as an inhibitor of breast cancer resistance protein
Akiko Watanabe
Poster
Other/Multi
ACoP16 | October 18-21, 2025
Tumor-agnostic
QSP I-O & ADCs: Integration of an antibody-drug conjugates mechanistic model into an immuno‐oncology quantitative systems pharmacology platform
Yafei Wang